Compare Amphastar Pharmaceuticals Inc (AMPH) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Home Depot Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.45 (market cap $863.95M), while Home Depot Inc trades at $354.69 (market cap $349.77B). The key difference: Home Depot Inc is far larger — about 404.8× Amphastar Pharmaceuticals Inc's market cap, and Home Depot Inc pays a 2.66% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HD | |
|---|---|---|
Market Cap | $863.95M | $349.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $423.42 |
52-Week Low | $16.87 | $297.51 |
Enterprise Value | $1.26B | $411.32B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Home Depot (HD) trades at $354.80, down 0.23% on the day, with a bullish technical outlook supported by moving averages. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q1 2026 but missing in Q3 2025. Revenue reached $159.51 billion in 2025 with a net income margin of 8.41%, though margins have compressed from previous years. Analyst consensus remains positive with 59% buy ratings and a $368.75 price target, representing 3.9% upside potential from current levels.
HD faces headwinds from weakening big-ticket demand and margin pressure from investments, but strong Pro business growth and housing market tailwinds support the long-term case. The stock's current valuation at 24.91 P/E appears reasonable given the company's market leadership and consistent profitability, though investors should monitor housing market trends and consumer spending patterns that directly impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
